The modern paradigm for assessment of the integral parameters аnd the glycemic variability - the role for the type 2 diabetes mellitus management
https://doi.org/10.21518/2079-701X-2019-4-38-43
Abstract
The paper presents the new paradigm for assessment the glycemic control at the patients with the type 2 diabetes (T2DM), which consists of the combined detection from the professional continuous Glucose Monitoring CGM data: 1) coefficient of variation CV and 2) corrected Glucemic Monitoring Index GMIc. This approach was tested with 510 T2DM CGM records and it allows to correct the aimed glycated haemoglobin level HbA1c in combination with the reduction of the glycemic variability for the routine endocrinological practice, and to assess the safety and the efficacy of the current sugar-rescue therapy, and to increase the technical compliance of the patient with T2DM.
About the Authors
N. A. Chernikova
Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Chernikova Natalia Albertovna - Cand. of Sci. (Med.), Associate Professor, Chair for Endocrinology.
125993, Moscow, Barrikadnaya St., 2/1, b. 1; tel.: +7(495) 531-30-40, ext. 1252
L. L. Kamynina
Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kamynina Lyudmila Leonidovna - Cand. of Sci. (Med.), Endocrinologist, Chair for Endocrinology.
125993, Moscow, Barrikadnaya St., 2/1, b. 1; tel.: +7(926) 253-82-41
A. S. Ametov
Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Ametov Aleksandr Sergeevich - Dr. of Sci. (Med.), Professor, Honoured Scientist of the Russian Federation, Head of Chair for Endocrinology.
125993, Moscow, Barrikadnaya St., 2/1, b. 1; tel.: +7 (495) 531-3040, ext. 1252
References
1. KLimontov V.V., Myakina N.E. GLycemia variability in diabetes meLLitus: a tool to assess the gLycemic controL quaLity and the risk of compLications. Sakhamy Diabet. 2014;2:76-82 (In Russ).
2. Rodbard D. GLucose VariabiLity: A Review of CLinicaL AppLications and Research DeveLopments. Diabetes Technol Ther. 2018;20(S2):25-215.
3. Danne T., Nimri R., BatteLino T., BergenstaL R.M., CLose K.L., DeVries J.H. et aL. InternationaL Consensus on Use of Continuous GLucose Monitoring. Diabetes Care. 2017;40(12):1631-1640.
4. Kovatchev B.P., FLacke F., Sieber J., Breton M.D. Accuracy and robustness of dynamicaL tracking of average gLycemia (A1c) to provide reaL-time estimation of hemogLobin A1c using routine seLf-monitored bLood gLucose data. Diabetes Technol Ther. 2014;16(5):303-309.
5. BergenstaL R.M., Beck R.W., CLose K.L., Grunber-ger G., Sacks D.B., KowaLski A. et aL. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous GLucose Monitoring. Diabetes Care. 2018;41(11):2275-2280.
6. LeeLarathna L., Beck R.W., BergenstaL R.M., Thabit H., Hovorka R.; APCam11 Investigators. et aL. GLucose Management Indicator (GMI): Insights and VaLidation Using Guardian 3 and Navigator 2 Sensor Data. Diabetes Care. 2019;42(4):e60-e61.
7. BatteLino T., Danne T., BergenstaL R.M., AmieL S.A., Beck R., Biester T. et aL. CLinicaL Targets for Continuous GLucose Monitoring Data Interpretation: Recommendations From the InternationaL Consensus on Time in Range. Diabetes Care. 2019 Jun 8. [Epub ahead of print].
8. Ametov A.S., Kamynina L.L. GLycemia variabiLity is the key to successfuL management of type 2 diabetes in the presence of obesity. RMJ. 2011;27:1673-1678. (In Russ).
9. Sakamoto M. Type 2 Diabetes and GLycemic VariabiLity: Various Parameters in CLinicaL Practice. J Clin Med Res. 2018;10(10):737-742.
10. CerieLLo A., Monnier L., Owens D. GLycaemic variabiLity in diabetes: cLinicaL and therapeutic impLications. Lancet Diabetes Endocrinol. 2019;7(3):221-230.
11. Ametov A.S., Kamynina L.L., Nazhmudinova P.K. CLinicaL aspects of the use of continuous gLycemia monitoring in diabetoLogy. RMJ. 2013;21(28):1401-1404. (In Russ).
12. Ametov A.S., Chernikova N.A. GLycemic controL in patients with type 2 diabetes. Consilium Medicum. 2016;18(4):24-27. (In Russ).
13. Chernikova N.A. Current management of gLycemia in patients with type 2 diabetes. Effektivnaya Farmakoterapia. 2017;9:22-25. (In Russ).
Review
For citations:
Chernikova NA, Kamynina LL, Ametov AS. The modern paradigm for assessment of the integral parameters аnd the glycemic variability - the role for the type 2 diabetes mellitus management. Meditsinskiy sovet = Medical Council. 2019;(4):38-43. (In Russ.) https://doi.org/10.21518/2079-701X-2019-4-38-43
Views:
750
Email this article 